MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down – Here’s What Happened

MoonLake Immunotherapeutics (NASDAQ:MLTX)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $18.26, but opened at $17.24. MoonLake Immunotherapeutics shares last traded at $17.1920, with a volume of 1,709,297 shares changing hands.

Key Stories Impacting MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Positive Phase 3 psoriatic arthritis results: MoonLake said the IZAR-1 trial met all primary and secondary endpoints at Week 16 in biologic-naïve adults. The 60 mg dose produced an ACR50 response in 42.1% of patients, while ACR20 reached 66.5%; among patients with skin involvement, 61% achieved PASI90. The results support sonelokimab’s potential as a treatment for psoriatic arthritis. Reuters article
• Positive Sentiment: Solid financial position: MoonLake ended the second quarter with $537 million in cash, cash equivalents and short-term investments. Management expects its cash runway to extend into mid-2028, with up to $400 million still available under its debt facility. The company also expects to submit a hidradenitis suppurativa biologics license application by the end of September 2026.
• Positive Sentiment: Earnings exceeded expectations: The company reported a quarterly loss of $0.84 per share, better than the analyst consensus estimate for a $0.92 loss. However, MoonLake still reported a net loss of $61.8 million for the quarter. MoonLake quarterly press release
• Neutral Sentiment: Options activity increased: Investors purchased 2,707 call options, 142% above the average daily volume. This suggests increased bullish positioning or speculation, but options activity alone does not confirm a sustained move in the stock.
• Neutral Sentiment: Brokerage outlook remains cautious: Analysts collectively give MLTX an average “Hold” recommendation, indicating that strong clinical progress is already partly reflected in the valuation.
• Negative Sentiment: Insider selling is a concern: Company insiders made 20 reported sales and no purchases during the past six months, including substantial selling by the chief executive, chief scientific officer and chief financial officer. That activity may undermine investor confidence despite the positive trial results.

Wall Street Analysts Forecast Growth

Several analysts recently commented on MLTX shares. Needham & Company LLC upped their price target on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price target on shares of MoonLake Immunotherapeutics in a report on Monday, July 20th. Weiss Ratings restated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 12th. BTIG Research reiterated a “buy” rating and set a $30.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 9th. Finally, Leerink Partners increased their target price on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, MoonLake Immunotherapeutics presently has an average rating of “Hold” and a consensus target price of $24.21.

MoonLake Immunotherapeutics Stock Performance

The stock has a market cap of $1.26 billion, a PE ratio of -4.44 and a beta of 1.06. The stock has a fifty day simple moving average of $19.05 and a two-hundred day simple moving average of $17.88. The company has a debt-to-equity ratio of 0.39, a quick ratio of 8.60 and a current ratio of 8.60.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.08. Equities analysts anticipate that MoonLake Immunotherapeutics will post -3.64 EPS for the current fiscal year.

Insider Transactions at MoonLake Immunotherapeutics

In other news, insider Kristian Reich sold 50,000 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $19.43, for a total transaction of $971,500.00. Following the transaction, the insider directly owned 2,824,551 shares of the company’s stock, valued at approximately $54,881,025.93. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Da Silva Jorge Santos sold 68,289 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the completion of the transaction, the chief executive officer owned 2,774,893 shares in the company, valued at approximately $55,553,357.86. This trade represents a 2.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 344,800 shares of company stock valued at $6,820,071 over the last three months. 10.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in MLTX. Kestra Advisory Services LLC acquired a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter valued at approximately $26,000. Bank of America Corp DE grew its position in shares of MoonLake Immunotherapeutics by 64.7% during the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after purchasing an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of MoonLake Immunotherapeutics by 115.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after purchasing an additional 3,166 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after purchasing an additional 1,069 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter valued at $47,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.